ICUCW
What one share of SeaStar Medical Holding holds
Surgical and Medical Instruments and Apparatus
We are a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. Our Selective Cytopheretic Device (“SCD”) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body.
SeaStar Medical Holding’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.48 |
|---|---|
| Profit | −$3.81 |
| Cash and investments | $1.63 |
| Debt | $0.12 |
| Book value | $1.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$158.73 | — | −$176.62 | — | −$97.25 |
| 2022 | — | −$371.14 | — | −$237.30 | — | −$408.71 |
| 2023 | $0.00 | −$302.63 | — | −$118.65 | — | — |
| 2024 | $0.36 | −$66.33 | — | −$42.76 | — | −$3.36 |
| 2025 | $0.60 | −$5.86 | — | −$6.56 | — | $2.71 |